Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Greiner Bio-One Accelerates HPV Laboratory Diagnostics

Published: Monday, November 04, 2013
Last Updated: Monday, November 04, 2013
Bookmark and Share
At the international congress on HPV (human papilloma virus) and cervical cancer, Greiner Bio-One is presenting the latest clinical study on the PapilloCheck HPV test.

For what is now the seventh time, Greiner Bio-One GmbH will be presenting its products in the field of cervical cancer at the international EUROGIN congress. The new CheckExtractor is a leap in technology and a crucial step toward a fully automated HPV detection. The device replaces the manual process of extracting DNA from patient samples and preparing the PCR setup for subsequent analysis using PapilloCheck and PapilloCheck high-risk. This simplifies and cuts down on the work done by laboratory staff while simultaneously making it possible to process far more samples in consistently high quality. This is confirmed by Dr. Ron Opstelten, the new Director Sales & Marketing for the Diagnostics Business Unit at Greiner Bio-One GmbH: "The introduction of the CheckExtractor for automatic DNA purification marks the successful completion of the first phase of the work Greiner Bio-One is doing to fully automate the oCheck microarray applications". This was the company¹s response to customers¹ greatly increased analysis requirements in the field of human medicine laboratory diagnostics. "Together with the CheckProcessor now under development, this will mean that all the work needed to process samples can be completed as quickly as possible, based on the principle 'sample in - result out'," explains Opstelten.

Another key element of Greiner Bio-One¹s programme at Eurogin will be Dr.
Bart Hesselink¹s presentation on the recently concluded clinical study on PapilloCheck. His speech on 'Clinical validation of the PapilloCheck assay according to international guidelines for HPV test requirements for cervical screening' will examine the successful approval of the PapilloCheck HPV-DNA test by the Dutch Society for Pathology. The DNA test kit can analyse 18 high-risk types of HPV and 6 low-risk types in parallel, thus enabling early identification of a total of 24 carcinogenic virus types. With these innovative products for diagnostic medicine, Greiner Bio-One has made important progress toward enabling an early risk management for cervical cancer development, the second most common form of cancer in women.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Zika Reference Strain Sequenced
An international research team has sequenced a strain of Zika for use as a WHO reference strain.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!